Achieving LDL-C Target Levels: The Role of Statins

References

• Martin, M. J., Hulley, S. B., Browner, W. S., Killer, L. H. and Wentworth, D. (1986). Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet, 2(8513), 933–936.
   PubMed Web of Science ®Google Scholar
• Castelli, W. P., Anderson, K., Wilson, P. W. and Levy, D. (1992). Lipids and risk of coronary heart disease. The Framingham Study. Ann. Epidemiol., 2(1-2), 23–28.
   PubMedGoogle Scholar
• Assmann, G., Schulte, H. and von Eckardstein, A. (1996). Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am. J. Cardiol., 77(14), 1179–1184.
   PubMed Web of Science ®Google Scholar
• Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease (1992). Prevention of coronary heart disease. Scientific background and new clinical guidelines. Nutr. Metab. Cardiovasc. Dis., 2, 113–156.
   Google Scholar
• Pyorala, K., De Backer, G., Graham, I., Poole-Wilson, P. and Wood, D. (1994). Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur. Heart. J., 15(10), 1300–1331.
   PubMed Web of Science ®Google Scholar
• Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention (1998). Eur. Heart. J., 19(10), 1434–1503.
   PubMed Web of Science ®Google Scholar
• Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) (1993). JAMA, 269(23), 3015–3023.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association (2000). Management of dyslipidemia in adults with diabetes. Diabetes Care, 23 (Suppl 1), 557–560.
   Google Scholar
• Grundy, S. M. (1988). HMG-CoA reductase inhibitors for treatment of hyperchol-esterolemia. N. Engl. J. Med., 319(1), 24–33.
   PubMed Web of Science ®Google Scholar
• Farnier, M. and Davignon, J. (1988). Current and future treatment of hyperlipdaemia: the role of statins. Am. J. Cardiol., 82(48), 3J–10J.
   Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) (1994). Lancet, 344(8934), 1383–1389.
   PubMed Web of Science ®Google Scholar
• Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., MacFarlane, P. W. et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med., 333(20), 1301–1307.
   PubMed Web of Science ®Google Scholar
• Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G. et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med., 335(14), 1001–1009.
   PubMed Web of Science ®Google Scholar
• Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A. et al. (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 279(20), 1615–1622.
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 339(19), 1349–1357.
   PubMed Web of Science ®Google Scholar
• Bucher, H. C., Griffith, L. E. and Guyatt, G. H. (1999). Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler. Thromb. Vasc. Biol., 19(2), 187–195.
   PubMed Web of Science ®Google Scholar
• Cullen, P. and Assmann, G. (1997). Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering? Am. J. Cardiol., 80(10), 1287–1294.
   PubMed Web of Science ®Google Scholar
• Sacks, F. M., Moye, L. A., Davis, B. R., Cole, T. G., Rouleau, J. L., Nash, D. T. et al. (1998). Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation, 97(15), 1446–1452.
   PubMed Web of Science ®Google Scholar
• Pedersen, T. R., Olsson, A. G., Faergeman, O., Kjekshus, J., Wedel, H., Berg, K. et al. (1998). Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation, 97(15), 1453–1460.
   PubMed Web of Science ®Google Scholar
• Eisenberg, D. A. (1998). Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. Am. J. Med., 104(2A), 2S–5S.
   PubMedGoogle Scholar
• Hunninghake, D. B. (1998). Therapeutic efficacy of the lipid-lowering arma-mentarium: the clinical benefits of aggressive lipid-lowering therapy. Am. J. Med., 104(2A), 9S–13S.
   PubMedGoogle Scholar
• The Post Coronary Artery Bypass Graft Trial Investigators (1997). The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous -vein coronary-artery bypass grafts. N. Engl. J. Med., 336(3), 153–162.
   PubMed Web of Science ®Google Scholar
• Knatterud, G. L., Rosenberg, Y., Campeau, L., Geller, N. L., Hunninghake, D. B., Forman, S. A. et al. (2000). Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial. Post CABG Investigators. Circulation, 102(2), 157–165.
   PubMed Web of Science ®Google Scholar
• Kastelein, J. J. (1999). The future of best practice. Atherosclerosis, 143 (Suppl 1), S17–S21.
   PubMedGoogle Scholar
• EUROASPIRE Study Group (1997). A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. European Action on Secondary Prevention through Intervention to Reduce Events. Eur. Heart J., 18(10), 1569–1582.
   PubMed Web of Science ®Google Scholar
• American Heart Association (1998). 1998 Heart and Stroke Statistical Update.
   Google Scholar
• Keech, A. (1998). Risk factor management in CHD patients in Asia: current status. Atherosclerosis, 136 (Suppl), S31.
   Web of Science ®Google Scholar
• Wood, D. A. (2000). EUROASPIRE II. Presented at XXII Congress of the European Society of Cardiology, August 26–30, 2000, Amsterdam.
   Google Scholar
• Pearson, T. A., Laurora, I., Chu, H. and Kafonek, S. (2000). The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipidlowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med., 160(4), 459�467.
   Google Scholar
• Muls, E., De Backer, G., De Bacquer, D., Brohet, M. and Heller, F. (2000). LIPIWATCH, a Belgian/Luxembourg survey on achievement of European Atherosclerosis Society lipid goals. Clin. Drug Invest., 19(3), 219�229.
   Web of Science ®Google Scholar
• Pearson, T. A. (2000). The undertreatment of LDL-cholesterol: addressing the challenge. Int. J. Cardiol., 74 (Suppl 1), S23�S28.
   PubMedGoogle Scholar
• Stein, E. A., Davidson, M. H., Dobs, A. S., Schrott, H., Dujovne, C. A., Bays, H. et al. (1998). The Expanded Dose Simvastatin U.S. Study Group. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. Am. J. Cardiol., 82(3), 311�316.
   PubMed Web of Science ®Google Scholar
• Garmendia, F., Brown, A. S, Reiber, I. and Adams, P. C. (2000). Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS Study). Curr. Med. Res. Opin., 16(3), 208–219
   PubMed Web of Science ®Google Scholar
• Dansette, P.M., Jaoen, M. and Pons, C. (2000). HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins. Exp. Toxic. Pathol., 52, 145–148.
   PubMed Web of Science ®Google Scholar
• Bertolini, S., Bon, G. B., Campbell, L. M., Farnier, M., Langan, J., Mahla, G. et al. (1997). Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis, 130(1-2), 191–197.
   PubMed Web of Science ®Google Scholar
• Hunninghake, D., Bakker-Arkema, R. G., Wigand, J. P., Drehobl, M., Schrott, H., Early, J. L. et al. (1998). Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J. Fam. Pratt., 47(5), 349–356.
   PubMed Web of Science ®Google Scholar
• Dujovne, C. A., Knopp, R., Kwiterovich, P., Hunninghake, D., McBride, T. A. and Poland, M. on behalf of the Cerivastatin Study Group (2000). Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1030 hypercholesterolemic patients. Mayo Clin. Proc., 75(11), 1124–1132.
   PubMed Web of Science ®Google Scholar
• Ose, L., Luurila, O., Eriksson, J., Olsson, A., Lithell, H. and Widgren, B. (2000). Cerivastatin gender effect: sub-analyses of results from a multinational, randomised, double-blind study. Cerivastatin Study Group. Cum Med. Res. Opin., 16(2), 80–87.
   PubMed Web of Science ®Google Scholar
• Insult, W. Jr., Isaacsohn, J., Kwiterovich, P., Ra, P., Brazg, R., Dujovne, C. et al. (2000). Cerivastatin Study Group. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. J. Int. Med. Res., 28(2), 47–68.
   PubMed Web of Science ®Google Scholar
• Ma, P., Hegele, R., Yale, J. F. and Schwartz, B. (2000). CAVEAT: a randomised, double-blind, parallel group evaluation of cervastatin 0.4 mg and 0.8 mg compared to atorvastatin 10 mg and 20 mg once daily in patients with combined (type Hb) dyslipidaemia. Br. J. Cardiol., 7(12), 780–786.
   Google Scholar
• Brown, A. S., Bakker-Arkema, R. G., Yellen, L., Henley, R. W. Jr, Guthrie, R., Campbell, C. F. et al. (1998). Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J. Am. Coll. Cardiol., 32(3), 665–672.
   PubMed Web of Science ®Google Scholar